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学 位 論 文 要 約  
 
 博士論文題目 CpG island methylator phenotype is associated with EGFR related gene mutation and 
the efficacy of irinotecan- and oxaliplatin-based chemotherapy in Japanese patients with metastatic 
colorectal cancer. 
（日本人進行大腸癌におけるＣｐＧアイランドメチル化表現型とＥＧＦR 関連遺伝子変異およ
びイリノテカン、オキサリプラチンを含む化学療法の効果との相関性） 
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 Background: Colorectal cancer (CRC) is one of the most common malignancies leading to significant 
morbidity and mortality worldwide. Colorectal cancer (CRC) is the third leading cause of cancer-related 
death, and accounts for more than 14,000 deaths each year in Japan. Colorectal tumorigenesis involves 
the accumulation of sequential genetic and epigenetic alterations. Epigenetics broadly dues to heritable 
alterations in gene expression that are not accompanied by changes in the DNA sequence. It is 
increasingly reported that epigenetic alterations including aberrant DNA methylation. In recent decades, 
the most extensively studied epigenetic alteration in colorectal cancer is aberrant DNA methylation, in the 
form of hypermethylation in promoter-associated CpG islands, which leads to transcriptional silencing or 
inactivation of DNA repair and tumor suppressor genes. The CpG island methylator phenotype (CIMP) with 
multiple promoter methylated loci has been widely observed in human colorectal cancer (CRC). CIMP status tightly 
associated with special clinicopathological and molecular characteristics has been referred to a potential epigenetic 
predictive marker or biomarker. However, the effect of standard chemotherapy and anti-epidermal growth factor receptor 
(EGFR) antibody therapy based on CIMP status is not fully known. Methods: In 125 metastatic colorectal cancer 
(mCRC) patients, I analyzed the relationship between clinical outcome of mCRC therapy, CIMP status detected by 
methylation-specific PCR (MSP), and genetic status in 5 EGFR related genes (KRAS, BRAF, PIK3CA, NRAS, and AKT1) 
detected by direct sequencing. Results: CIMP-positive status was significantly associated with proximal tumor location, 
lung and peritoneum metastasis (all P values < 0.05). The progression free survival of the sequential first- and 
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second-line therapy with irinotecan-based regimen followed by FOLFOX (median = 15.2 months) was superior to the 
reverse sequence (median = 6.6 months) in CIMP-positive tumors (P = 0.043). Furthermore, CIMP-positive tumors 
showed higher frequency of mutation in any of 5 EGFR related genes (74.0%) than CIMP-negative tumors (48.0%). 
Among KRAS wild-type tumors, CIMP-positive tumors showed worse clinical outcomes of mCRC patients in the 
anti-EGFR antibody therapy than CIMP-negative tumors. Conclusion: Sequential irinotecan-based regimen followed by 
FOLFOX was superior to reverse sequential treatment in CIMP-positive tumors. High frequency of mutations in 
EGFR related genes in CIMP-positive tumors cause the lower response for anti-EGFR antibody therapy in KRAS 
wild-type and CIMP-positive tumors.  
 
